Scarica l'app Stockscreener
7.87
0.38%
0.03
Dopo l'orario di chiusura:
7.90
0.03
+0.38%
Precedente Chiudi:
$7.84
Aprire:
$7.89
Volume 24 ore:
1.65M
Relative Volume:
0.92
Capitalizzazione di mercato:
$923.10M
Reddito:
-
Utile/perdita netta:
$-29.07M
Rapporto P/E:
-27.14
EPS:
-0.29
Flusso di cassa netto:
$-31.85M
1 W Prestazione:
+14.72%
1M Prestazione:
+38.56%
6M Prestazione:
+101.28%
1 anno Prestazione:
+148.26%
Intervallo 1D:
$7.65
$7.97
Intervallo di 1 settimana:
$6.67
$8.11
Portata 52W:
$2.36
$8.11
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Nome
Trevi Therapeutics Inc
Settore
Industria
Telefono
203-304-2499
Indirizzo
195 CHURCH STREET, NEW HAVEN, CT
Confronta TRVI con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TRVI
Trevi Therapeutics Inc
|
7.87 | 954.56M | 0 | -29.07M | -31.85M | -0.29 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-01 | Iniziato | Cantor Fitzgerald | Overweight |
| 2025-05-28 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-10 | Reiterato | Needham | Buy |
| 2025-03-10 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2024-12-12 | Reiterato | H.C. Wainwright | Buy |
| 2024-09-09 | Ripresa | Leerink Partners | Outperform |
| 2024-08-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-30 | Iniziato | Raymond James | Outperform |
| 2024-06-13 | Iniziato | Rodman & Renshaw | Buy |
| 2023-04-12 | Iniziato | B. Riley Securities | Buy |
| 2022-11-22 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | BMO Capital Markets | Outperform |
| 2019-06-03 | Iniziato | Needham | Buy |
| 2019-06-03 | Iniziato | SVB Leerink | Outperform |
| 2019-06-03 | Iniziato | Stifel | Buy |
Mostra tutto
Trevi Therapeutics Inc Borsa (TRVI) Ultime notizie
Trevi Therapeutics Inc. Stock Analysis and ForecastUnbelievable profit margins - PrintWeekIndia
What analysts say about Trevi Therapeutics Inc. stockConsistent wealth multiplication - PrintWeekIndia
What drives Trevi Therapeutics Inc. stock priceUnprecedented profit potential - PrintWeekIndia
Is Trevi Therapeutics Inc. a good long term investmentHigh-profit trading signals - Autocar Professional
Will Trevi Therapeutics Inc. stock split in the near futureMarket-leading growth rates - jammulinksnews.com
How Trevi Therapeutics Inc. stock reacts to Fed policy changesRapid growth trajectories - jammulinksnews.com
Should I buy Trevi Therapeutics Inc. stock before earningsTurbocharged investment results - jammulinksnews.com
The Business Case For Buying Trevi Therapeutics Inc (NASDAQ: TRVI) Stock Now - Stocksregister
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Seeking Alpha
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism - Eastern Progress
How Trevi Therapeutics Inc. stock performs during market volatilityFree Access to Investors Club - Newser
Trevi Therapeutics, Inc.'s (NASDAQ:TRVI) high institutional ownership speaks for itself as stock continues to impress, up 17% over last week - simplywall.st
Why Trevi Therapeutics Inc. stock attracts strong analyst attentionSolid Return Trade Selections - Newser
What makes Trevi Therapeutics Inc. stock price move sharplyFree Smart Investment Opportunities - Newser
Trevi Therapeutics Announces Notice of Allowance for U.S. Patent Application Covering Use of Haduvio™ (nalbuphine ER) for the Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis - The Globe and Mail
Trevi Therapeutics (TRVI) Price Target Predicts 231.05% Upside Potential - AInvest
Wall Street Analysts Predict a 231.05% Upside in Trevi Therapeutics (TRVI): Here's What You Should Know - Yahoo Finance
31,359 Shares in Trevi Therapeutics, Inc. (NASDAQ:TRVI) Purchased by Vontobel Holding Ltd. - Defense World
Cantor Fitzgerald Comments on TRVI FY2025 Earnings - Defense World
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism | TRVI Stock News - GuruFocus
Trevi Therapeutics to Attend Leerink Partners Therapeutics Forum: I&I and Metabolism. - AInvest
Trevi Therapeutics, Inc.(NasdaqGM: TRVI) dropped from Russell 3000 Value Index - MarketScreener
Cough in Idiopathic Pulmonary Pipeline 2025: Therapies, MOA Insights, and Key Clinical Trial Updates by DelveInsight | Algernon Pharma, Seyltx, Melius Pharma, NeRRe Therapeutics, Trevi Therapeutics - Barchart.com
TRVI STOCKHOLDER ALERT: Kaskela Law LLC Announces Investigation of Trevi Therapeutics, Inc. ... - Bluefield Daily Telegraph
Trevi Therapeutics Stockholders Approve Key Amendments - TipRanks
Leerink Partnrs Issues Optimistic Estimate for TRVI Earnings - Defense World
Trevi Therapeutics Inc Azioni (TRVI) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.97%
0.22%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):